Compared side by side
CagriSema vs semaglutide: how they differ
The short answer
CagriSema is semaglutide plus cagrilintide, a long-acting analogue of the fullness hormone amylin, in one weekly regimen; amylin and GLP-1 curb appetite through partly different routes, so their effects add up. In its main trial people on CagriSema lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone. Semaglutide is FDA-approved, as Ozempic and Wegovy; CagriSema isn’t approved yet, and Novo Nordisk filed it with the FDA in December 2025.
Side by side
| Compared | CagriSema | Semaglutide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Cagrilintide/semaglutide, Cagrilintide-semaglutide, Cagri-Sema, Cagri + Sema | Ozempic, Wegovy |
| What it is | Two weekly drugs in one regimen: cagrilintide, a long-acting version of the fullness hormone amylin, and semaglutide, the GLP-1 drug in Wegovy and Ozempic. | A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying. |
| How it works | Weekly combination of two long-acting hormone analogues: cagrilintide, an amylin analogue that acts on amylin and calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. Amylin and GLP-1 curb appetite through partly different brain pathways, so their effects add up: in REDEFINE 1 the pair lost more weight than either drug alone. Doses are written per component (2.4 mg/2.4 mg is 2.4 mg of each). Not approved: Novo Nordisk filed it with the FDA in December 2025, and a decision is expected in the fourth quarter of 2026. | GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects. |
| Commonly reported | Strong appetite suppression and early fullness, with nausea, vomiting or constipation through the dose steps. In its main trial people lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone; it is not approved yet. | The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial. |
| Studied range | Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation. | FDA label: 0.25–2.4 mg, starting dose 0.25 mg. |
| How often | Weekly | Weekly SubQ |
| Half-life | ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial) | ~1 week (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | Studied as an ongoing weekly treatment: 68 to 84 weeks in phase 3. Not approved yet; Novo Nordisk filed for US approval in December 2025. | FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, vomiting, diarrhea, constipation, abdominal pain | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk |
- Category
- CagriSemaMetabolic & GLP-1
- SemaglutideMetabolic & GLP-1
- Also known as
- CagriSemaCagrilintide/semaglutide, Cagrilintide-semaglutide, Cagri-Sema, Cagri + Sema
- SemaglutideOzempic, Wegovy
- What it is
- CagriSemaTwo weekly drugs in one regimen: cagrilintide, a long-acting version of the fullness hormone amylin, and semaglutide, the GLP-1 drug in Wegovy and Ozempic.
- SemaglutideA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.
- How it works
- CagriSemaWeekly combination of two long-acting hormone analogues: cagrilintide, an amylin analogue that acts on amylin and calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. Amylin and GLP-1 curb appetite through partly different brain pathways, so their effects add up: in REDEFINE 1 the pair lost more weight than either drug alone. Doses are written per component (2.4 mg/2.4 mg is 2.4 mg of each). Not approved: Novo Nordisk filed it with the FDA in December 2025, and a decision is expected in the fourth quarter of 2026.
- SemaglutideGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.
- Commonly reported
- CagriSemaStrong appetite suppression and early fullness, with nausea, vomiting or constipation through the dose steps. In its main trial people lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone; it is not approved yet.
- SemaglutideThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.
- Studied range
- CagriSemaResearch range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.
- SemaglutideFDA label: 0.25–2.4 mg, starting dose 0.25 mg.
- How often
- CagriSemaWeekly
- SemaglutideWeekly SubQ
- Half-life
- CagriSema~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial)
- Semaglutide~1 week (FDA label)
- Route
- CagriSemaSubQ injection
- SemaglutideSubQ injection
- Typical run
- CagriSemaStudied as an ongoing weekly treatment: 68 to 84 weeks in phase 3. Not approved yet; Novo Nordisk filed for US approval in December 2025.
- SemaglutideFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.
- Evidence
- CagriSemaEstablished: clinical trials or FDA-approved use exists
- SemaglutideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- CagriSemaNausea, vomiting, diarrhea, constipation, abdominal pain
- SemaglutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
CagriSema
- Day 1–28 · 0.25 mg The 0.25 mg start
- Day 29–364 · 0.5 mg 0.5 mg of each
- Day 57–364 · 1 mg 1 mg of each, halfway up
- Day 85–364 · 1.7 mg 1.7 mg of each, one step from the top
- Day 113+ · 2.4 mg 2.4 mg/2.4 mg, the maintenance dose
Semaglutide
- Day 1–28 · 0.25 mg Gut is adapting
- Day 29–56 · 0.5 mg Appetite shifts are real now
- Day 57–112 · 1 mg Clinically useful weight loss kicks in
- Day 113–140 · 1.7 mg Max submaximal step
- Day 141–364 · 2.4 mg Full dose — the working dose
- Day 365+ Plateau territory — new baseline
Questions people ask
How long do CagriSema and semaglutide last?
The half-life of CagriSema is ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial). The half-life of semaglutide is ~1 week (FDA label).
How often are CagriSema and semaglutide taken?
CagriSema: weekly. Route: SubQ injection. Semaglutide: weekly SubQ. Route: SubQ injection.
How are CagriSema and semaglutide dosed in research?
The research range for CagriSema is 0.25–2.4 mg, with a 0.25 mg starting dose. Studied in research — not a recommendation. The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose.
What are the common side effects of CagriSema and semaglutide?
For CagriSema, the library lists: nausea, vomiting, diarrhea, constipation, abdominal pain. For semaglutide: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk.